In a nutshell This study investigated the effects of pre-stem cell transplantation (pre-SCT) treatment with brentuximab vedotin (Adcetris) and bendamustine (Treanda) on patients with relapsing/refractory Hodgkin's Lymphoma (HL) following transplant. The main finding was that the drug combination was effective as a pre-SCT therapy. Some...
Read MoreCurrent treatment status-Undergoing active treatment-Progressive despite treatment Posts on Medivizor
Does ibrutinib pre-treatment affect the outcomes of alloHCT in mantle cell lymphoma?
In a nutshell This study investigated the safety and effectiveness of alloHCT (allogeneic hematopoietic stem cell transplantation) in patients with mantle cell lymphoma (MCL) pre-treated with ibrutinib (Imbruvica). This study concluded that ibrutinib does not affect the safety of alloHCT. Some background Ibrutinib has become the standard of care for...
Read MoreWhat type of stem cell transplant is most effective after early treatment failure in follicular lymphoma?
In a nutshell This study investigated the effectiveness of stem cell transplantation in follicular lymphoma patients who experienced early treatment failure after frontline chemoimmunotherapy. This study concluded that transplants using the patient's own stem cells or those from a matched sibling donor lead to better survival outcomes in these...
Read MoreRadiotherapy for relapsed or refractory diffuse large b-cell lymphoma
In a nutshell This study investigated the effectiveness of consolidative or salvage radiotherapy for patients with relapsed or refractory (does not respond to treatment) diffuse large B-cell lymphoma. This study concluded that radiotherapy is an effective option for high-risk patients. Some background The most widely used treatment for diffuse large...
Read MoreTargeted immunotherapies for classical Hodgkin’s lymphoma
In a nutshell This article reviewed the results of new targeted immunotherapy treatments in patients with classical Hodgkin’s lymphoma that is relapsed or refractory (does not respond to treatment). Some background Thanks to treatment advances, classical Hodgkin’s lymphoma (cHL) has become one of the most curable cancers. Frontline ABVD...
Read MoreIs targeted therapy better at treating advanced NSCLC than current chemotherapy treatment?
In a nutshell This study examined the effectiveness of the targeted therapy drug nivolumab (Opdivo) at treating advanced non-small-cell lung cancer, particularly for patients with cancer that has spread to the liver. The authors concluded that nivolumab led to an improved overall survival compared to chemotherapy for these patients. Some background...
Read MorePanitumumab injections to treat metastatic colorectal cancer
In a nutshell This study investigated the effectiveness and safety of short 15-minute panitumumab (Vectibix) injections. Researchers suggested that these injections were well tolerated with manageable side effects. Some background Panitumumab is a therapy that targets the EFGR receptor on cancer cells. This blocks cell growth which results in cell...
Read MoreWhat are the long-term outcomes for HL patients who experience treatment failure after an autologous stem cell transplant?
In a nutshell This study analyzed the survival outcomes of Hodgkin’s lymphoma (HL) patients who experience treatment failure after high-dose chemotherapy (HDC) and autologous hematopoietic stem cell transplantation (autoSCT). This study concluded that a second stem cell transplant with or without brentuximab vedotin (Adcetris) may lead to better...
Read MoreElozutumab in relapsed or refractory multiple myeloma
In a nutshell This paper reviewed the effect of elozutumab (Empliciti) in the treatment of relapsed or refractory multiple myeloma. This study concluded that elozutumab with lenalidomide (Revlimid) and dexamethasone (Ozurdex) can be considered in relapsed or refractory multiple myeloma. Some background Multiple myeloma...
Read MoreHow safe and effective is ponatinib for chronic phase chronic myeloid leukemia patients?
In a nutshell This study aimed to investigate the effectiveness and safety of ponatinib (Iclusig) for patients with chronic phase chronic myelogenous leukemia. This study concluded that ponatinib is safe and effective in this group of patients. Some background The Philadelphia chromosome (BCR-ABL1) is found in almost all patients with chronic...
Read MoreRisk factors that influence outcomes for acute leukemia patients with relapse after hematopoietic stem cell transplant.
In a nutshell This study aimed to investigate risk factors that influence the outcome of acute leukemia patients who experience relapse after hematopoietic stem cell transplant. This study concluded that certain factors, such as older age and not acheiving remission after relapse treatment, are associated with worse survival outcomes. Some...
Read MoreHow safe and effective is the combination of ibrutinib, lenalidomide, and rituximab for relapsed or refractory mantle cell lymphoma?
In a nutshell This study investigated the safety and effectiveness of ibrutinib (Imbruvica), lenalidomide (Revlimid), and rituximab (Rituxan) given together to patients with relapsed or refractory (not responding to treatment) mantle cell lymphoma (MCL). The authors conclude that this combination is effective in these patients, but not better than the...
Read More
